|
|
Volumn 24, Issue 9 PART II, 1997, Pages 697-704
|
|
Clinical safety of enamel matrix derivative (EMDOGAIN®) in the treatment of periodontal defects
|
|
Author keywords
Atopic; Clinical trial; Enamel proteins; Immunoassay; Regeneration; Surgery
|
|
Indexed keywords
ANTIBODY;
ENAMEL MATRIX PROTEINS;
ENAMEL PROTEIN;
ADULT;
AGED;
ANTIBODY PRODUCTION;
ARTICLE;
BLOOD;
CLINICAL TRIAL;
COMPARATIVE STUDY;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
FEMALE;
FOLLOW UP;
HUMAN;
HYPERSENSITIVITY;
IMMUNOLOGY;
MALE;
MIDDLE AGED;
MULTICENTER STUDY;
MULTIMODALITY CANCER THERAPY;
OSTEOLYSIS;
PERIODONTAL DISEASE;
PERIODONTITIS;
PLASTIC SURGERY;
POSTOPERATIVE COMPLICATION;
RADIOGRAPHY;
SAFETY;
ADULT;
AGED;
ALVEOLAR BONE LOSS;
ANTIBODIES;
ANTIBODY FORMATION;
COMBINED MODALITY THERAPY;
DENTAL ENAMEL PROTEINS;
FEMALE;
FOLLOW-UP STUDIES;
HUMANS;
HYPERSENSITIVITY;
MALE;
MIDDLE AGED;
PERIODONTAL ATTACHMENT LOSS;
PERIODONTITIS;
POSTOPERATIVE COMPLICATIONS;
SAFETY;
SURGICAL FLAPS;
|
|
EID: 0031227529
PISSN: 03036979
EISSN: None
Source Type: Journal
DOI: 10.1111/j.1600-051x.1997.tb00252.x Document Type: Article |
|
Times cited : (143)
|
|
References (1)
|
